| Guojing Zhang,Yongye Liu,Chao Lin,Jianfei Guo,Long Xu,Junling Liu,Ying Piao,Guanzhong Zhang,Yuhui Liu,Yaling Han,Xiaodong Xie. Influence of tumor response on the survival of patients with extensive-stage small-cell lung cancer treated with the etoposide plus cisplatin chemotherapy regimen. Oncol Transl Med, 2015, 1: 65-68. |
| 广泛期小细胞肺癌对EP方案的化疗敏感性与生存期的关系 |
| Influence of tumor response on the survival of patients with extensive-stage small-cell lung cancer treated with the etoposide plus cisplatin chemotherapy regimen |
| Received:January 12, 2015 Revised:February 04, 2015 |
| DOI：10.1007/s10330-015-0058-z |
| 中文关键词: CCC |
| 英文关键词: extensive-stage small-cell lung cancer (ES-SCLC); tumor response; progression-free survival (PFS); overall survival (OS) |
| 基金项目: |
| Author Name | Affiliation | E-mail | | Guojing Zhang | Department of Oncology, PLA cancer center, The General Hospital of Shenyang Military Region, Shenyang 110840, China | zhanggjing888@126.com | | Yongye Liu | Department of Oncology, PLA cancer center, The General Hospital of Shenyang Military Region, Shenyang 110840, China | liuyongye666@163.com | | Chao Lin | Department of Gynaecology, The Wenzhou Traditional Chinese Medicine Hospital of Zhejiang Chinese Medical University, Wenzhou 325000, China | 185177989@qq.com | | Jianfei Guo | Department of Oncology, PLA cancer center, The General Hospital of Shenyang Military Region, Shenyang 110840, China | doctor_xxd@163.com | | Long Xu | Department of Oncology, PLA cancer center, The General Hospital of Shenyang Military Region, Shenyang 110840, China | syysxh@yahoo.com.cn | | Junling Liu | Department of Oncology, PLA cancer center, The General Hospital of Shenyang Military Region, Shenyang 110840, China | wawjljl870503@163.com | | Ying Piao | Department of Oncology, PLA cancer center, The General Hospital of Shenyang Military Region, Shenyang 110840, China | 15309880806@163.com | | Guanzhong Zhang | Department of Oncology, PLA cancer center, The General Hospital of Shenyang Military Region, Shenyang 110840, China | doctor_xxd@163.com | | Yuhui Liu | Department of Oncology, PLA cancer center, The General Hospital of Shenyang Military Region, Shenyang 110840, China | yalinghan2013@163.com | | Yaling Han* | Department of Cardiology, Institute of Cardiovascular Research of PLA, The General Hospital of Shenyang Military Region, Shenyang 110840, China | yalinghan2013@163.com | | Xiaodong Xie | Department of Oncology, PLA cancer center, The General Hospital of Shenyang Military Region, Shenyang 110840, China | doctor_xxd@163.com |
|
| Hits: 9351 |
| Download times: 9966 |
| 中文摘要: |
| 前言: 广泛期小细胞肺癌通常对EP方案化疗具有较高的敏感性，但PFS和OS均较短，本研究旨在观察一线应用EP方案治疗的广泛期小细胞肺癌患者疗效，对比2周期疗效达到PR/CR的患者与4/6周期达到PR/CR的患者之间生存期的差异。
方法: 收集沈阳军区总医院2004年11月至2011年5月106例应用EP方案一线解救化疗的广泛期小细胞肺癌病例，对其随访观察，记录PFS和OS，应用SPSS 21.0系统分析生存数据。
结果: 中位随访时间为293天(62-1531天)，所有患者临床死亡，79例患者最佳疗效达到PR/CR，总体PR/CR率为74.5%，中位PFS和中位OS分别为5.8个月（95%Cl：5.2-6.4）和9.6个月（95%Cl：8.4-10.8），其中51例在化疗2周期后达到PR/CR，中位PFS为6.0个月（95%Cl：5.1-6.9），28例在化疗4/6周期后达到PR/CR，中位PFS为4.8个月（95%Cl：4.4-5.2），二组具有统计学差异（P=0.029）。随访结束后，进一步统计OS情况，化疗2周期达到PR/CR者中位OS为10.5个月（95%Cl：8.6-12.4），化疗4/6周期达到PR/CR者中位OS为7.5个月（95%Cl：6.8-8.2），具有统计学差异（P=0.001）。
结论: EP方案一线解救化疗2周期达到PR/CR的广泛期小细胞肺癌患者较4/6周期达到PR/CR的患者可获得更高的PFS和OS。 |
| 英文摘要: |
| Objective?In this study, we evaluated the difference of progression-free survival (PFS) and overall survival (OS) between extensive-stage small-cell lung cancer (ES-SCLC) patients who acquired partial response (PR) or complete remission (CR) after two cycles of first-line chemotherapy with the etoposide plus cisplatin (EP) regimen and those who acquired PR or CR after four or six cycles.
Methods?A total of 106 eligible patients treated with the EP chemotherapy regimen for two to six cycles, at The General Hospital of Shenyang Military Region (China) between November 2004 and May 2011, were enrolled in this study. RECIST version 1.1 was used for the evaluation of chemotherapy efficiency. We followed up all eligible patients every 4 weeks. All statistical data were analyzed by using SPSS 21.0 statistical package for Windows.
Results?After a median follow-up of 293 days (range, 62–1531 days), all patients had died by the cutoff date. Fifty-one patients acquired PR or CR after two cycles of chemotherapy; the median PFS reached 6.0 months (95% CI, 5.1–6.9), and the median OS was 10.5 months (95% CI, 8.6–12.4). Twenty-eight patients acquired PR or CR after four or six cycles; the median PFS was 4.8 months (95% CI, 4.4–5.2), and the median OS was 7.5 months (95% CI, 6.8–8.2). Both PFS and OS showed a statistical difference between the two groups.
Conclusion?ES-SCLC patients who acquired PR or CR after two cycles of the EP regimen as first-line therapy had longer PFS and OS than those who acquired PR or CR after four or six cycles.
|
|
View Full Text
Download reader HTML全文 |
| Close |
|
|
|